Lamivudine-refractory chronic hepatitis B

Lamivudine-refractory chronic hepatitis B refers to persistent or recurrent chronic hepatitis B virus (HBV) infection in patients who have failed prior or ongoing therapy with the nucleoside analogue lamivudine

Lamivudine-refractory chronic hepatitis B refers to persistent or recurrent chronic hepatitis B virus (HBV) infection in patients who have failed prior or ongoing therapy with the nucleoside analogue lamivudine Primarily affecting the hepatic system, the condition is pathophysiologically driven by the selection of drug-resistance mutations within the catalytic domain of the HBV reverse transcriptase, most notably within the conserved YMDD motif (such as rtM204V/I substitutions) Clinically, it is...

Primarily affecting the hepatic system, the condition is pathophysiologically driven by the selection of drug-resistance mutations within the catalytic domain of the HBV reverse transcriptase, most notably within the conserved YMDD motif (such as rtM204V/I substitutions) Clinically, it is characterized by virologic breakthrough or failure—evidenced by detectable and rising serum HBV DNA levels despite compliant therapy—frequently accompanied by biochemical relapse marked by elevated serum aminot...

Clinically, it is characterized by virologic breakthrough or failure—evidenced by detectable and rising serum HBV DNA levels despite compliant therapy—frequently accompanied by biochemical relapse marked by elevated serum aminotransferases and ongoing necroinflammatory liver disease